Granules Pharmaceuticals Inc.: Drug Recall
Recall #D-0510-2025 · 06/24/2025
Class II: Risk
Recall Details
- Recall Number
- D-0510-2025
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- Granules Pharmaceuticals Inc.
- Status
- Ongoing
- Date Initiated
- 06/24/2025
- Location
- Chantilly, VA, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 27,648 100-count Bottles; 5,376 500-count Bottles
Reason for Recall
Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.
Product Description
Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01; b) 500-count bottle, NDC 70010-780-05; Rx only, Manufactured by: Granules India Limited, Hyderadab-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA 20151,
Distribution Pattern
Nationwide in the USA.
Other Recalls by Granules Pharmaceuticals Inc.
- Class II: Risk 01/26/2026
- Class III: Low Risk 08/28/2025
- Class III: Low Risk 08/28/2025
- Class III: Low Risk 08/28/2025
- Class III: Low Risk 08/28/2025
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.